Sorrento Therapeutics Inc
Change company Symbol lookup
Select an option...
SRNEQ Sorrento Therapeutics Inc
SPI SPI Energy Co Ltd
AMC AMC Entertainment Holdings Inc
BOF BranchOut Food Inc
KITT Nauticus Robotics Inc
EAT Brinker International Inc
JCSE JE Cleantech Holdings Ltd
GVP GSE Systems Inc
CURV Torrid Holdings Inc
APRN Blue Apron Holdings Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Closing Price
$0.094
Day's Change
-0.0062 (-6.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.1151
Day's Low
0.086
Volume
(Below Average)
Volume:
3,495,089

10-day average volume:
4,279,076
3,495,089

Policlinico Gemelli and Palantir Technologies Partner to Use AI to Advance Data Science for Healthcare

6:59 am ET September 8, 2023 (BusinessWire) Print

Palantir Technologies Inc. (NYSE: PLTR) ("Palantir") and Gemelli Generator Real World Data (RWD), a research facility of Fondazione Policlinico Universitario A. Gemelli IRCCS ("Policlinico Gemelli"), today announced a partnership to implement digital medicine research solutions that leverage artificial intelligence to improve patient care and health outcomes.

Policlinico Gemelli's digital research center, Generator RWD, will utilize Palantir Foundry as one of the key enabling platforms to manage the full scale and complexity of healthcare data. Foundry's AI capabilities will be utilized to generate Real World Evidence in support of clinical and translational research aimed at drug and indication discovery, improved patient care, and the development of digital medicine solutions for healthcare research in Italy and within their partnerships at global scale.

Palantir's software will boost the capabilities of Generator RWD and its partner network as they continue in their quest to strengthen the exploitation of data to gain new insights in several healthcare research domains.

"Healthcare is transforming through the power of data and AI, and this trend will only accelerate. More and more of the industry is wielding this power to discover novel therapies, improve patient care and increase treatment efficiency and effectiveness," said Andrea Galvagni, Head of Italy at Palantir. "At Palantir, we are proud to support world-leading institutions such as Policlinico Gemelli by providing them with the technology they need to achieve their most critical missions."

"Real World Evidence is constantly gaining traction in support of research in healthcare. By integrating Foundry in the framework developed at Generator RWE, we aim at accelerating our research pipeline cycles to deliver faster and better outcomes," said Vincenzo Valentini, Scientific Director of Gemelli Generator Research Facility.

"The added value of Palantir software and their deep skills in data-driven innovation will enrich the suite of products and services we are delivering within co-creation projects with our industrial partners," said Alfredo Cesario, CEO of Gemelli Digital Medicine & Health.

About Palantir Technologies Inc.

Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.

About Policlinico Gemelli

Gemelli Generator is an innovative center with multidisciplinary skills, which originates from the awareness of the need for tools capable to collect, store and analyze the huge amount of data generated every day from heterogeneous sources, translating them into understandable and usable information while fully respecting the privacy, data integrity and intellectual property, for the benefit of all.

Gemelli Generator, built in collaboration with the Universita Cattolica del Sacro Cuore, is one of the projects of the Gemelli Science and Technological Park (GSTeP) of the Fondazione Policlinico Universitario A. Gemelli IRCCS, with the aim to provide physicians and researchers with a wide ranging research facility.

To support diagnosis and treatment and clinical processes, Gemelli Generator offers Artificial Intelligence and Big Data processing services for the integration of clinical data and the development of predictive models; aiming at the clinical and scientific valorisation of the skills, processes and data of the Data Warehouse (DWH) of the Fondazione Policlinico Universitario A. Gemelli IRCCS, through advanced data extraction, collection and analysis services.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir's expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms' reliability; and our customer's ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230908825834/en/

SOURCE: Palantir Technologies Inc.

Media Contacts


Palantir 
Lisa Gordon
media@palantir.com


Policlinico Gemelli 
Nicola Cerbino
nicola.cerbino@policlinicogemelli.it
comtex tracking

COMTEX_439766266/1006/2023-09-08T06:59:04

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.